Stoke Therapeutics, Inc. 8-K

What Happened
Stoke Therapeutics filed an 8-K reporting that its Board approved a discretionary bonus of $697,125 for CEO Ian F. Smith on February 13, 2026. Mr. Smith became interim CEO in March 2025 and was named permanent CEO in October 2025; he did not participate in the company’s 2025 annual bonus program. The awarded Bonus equals the full amount of his target annual bonus had he participated.

Key Details

• Bonus amount: $697,125 (discretionary, approved Feb 13, 2026).
• Mr. Smith’s roles: interim Chief Executive Officer starting March 2025; permanent CEO as of October 2025.
• Mr. Smith did not participate in the 2025 annual bonus program; the Bonus represents his full target bonus for 2025.
• The Board determined corporate goal achievement under the 2025 annual bonus program to be 150% of target.

Why It Matters
This filing discloses an executive compensation action that will affect governance and compensation expense. For investors, it signals the Board’s positive assessment of company performance after Mr. Smith’s appointment (the Board tied the award to clinical and financial performance) and documents a one-time discretionary payment tied to 2025 results.